Pfizer Gets European OK for Zirabev Biosimilar to Genentech's Avastin
February 19 2019 - 10:30AM
Dow Jones News
By Colin Kellaher
Pfizer Inc. (PFE) on Tuesday said it received European
Commission approval for Zirabev, its biosimilar to Genentech's
cancer drug Avastin, in several forms of cancer.
The New York drug maker said the Zirabev approval covers the
treatment of metastatic carcinoma of the colon or rectum;
metastatic breast cancer; unresectable advanced, metastatic or
recurrent non-small cell lung cancer; advanced and/or metastatic
renal cell cancer; and persistent, recurrent or metastatic
carcinoma of the cervix.
Biosimilar products are the generic equivalents of biologic
drugs, which are created from living cells.
Pfizer said Zirabev is its fifth biosimilar, and second oncology
biosimilar, to receive European approval. The company last July
said the EC approved Trazimera, its biosimilar to Genentech's
Herceptin, in certain breast and gastric cancers
Genentech is a unit of Roche Holding AG (ROG.EB).
Pfizer said it has also filed for U.S. Food and Drug
Administration approval of Zirabev.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 19, 2019 10:15 ET (15:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024